Highlighted research articles

In This Issue| July 01 2024 Highlighted research articles Author 5 (4): 228. https://doi.org/10.1158/2643-3230.BCD-5-4-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Data on long-term responses are critical to understanding the curative potential of CAR-T–cell therapy (CART). In several lymphoma types, these data are still scarce, as the first CART trials have been conducted only recently. Mo and colleagues present a follow-up of two patients treated with anti-CD20 CART, one mantle cell (MCL) and one follicular lymphoma (FL), who sustained clinical responses for over 7 years, among the longest known to date for these disease subtypes. The responses are more remarkable because they occur alongside residual disease and in the absence of sustained CAR-T activity, as inferred by the lack of B-cell aplasia. Immunological assays of T-cell repertoire and humoral and cellular immune responses against autologous tumor suggest that endogenous anti-lymphoma immunity developed following CAR-T–cell infusions. Secondary T-cell responses to antigens released from target cells killed by the initial immune response, termed "epitope spreading," is fundamental to successful immune defense against pathogens.... You do not currently have access to this content.